¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"secondary antibody response"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • late asthmatic response
    ¸¸±âõ½Ä¹ÝÀÀ, Èıâõ½Ä¹ÝÀÀ
  • lytic response
    ¿ëÇØ¹ÝÀÀ
  • middle latency response
    Áß°£Àẹ¹ÝÀÀ
  • myotatic response
    ±ÙÀ°½ÅÀü¹ÝÀÀ
  • memory immune response
    ¸é¿ª±â¾ï¹ÝÀÀ
  • microphonic response
    ¸¶ÀÌÅ©·ÎÆù¹ÝÀÀ
  • placebo response
    ¼ÓÀÓ¾à¹ÝÀÀ, Çö󼼺¸¹ÝÀÀ
  • primary immune response
    ÀÏÂ÷¸é¿ª¹ÝÀÀ
  • pyramidal tract response
    ÇǶó¹Ìµå·Î¹ÝÀÀ, Ãßü·Î¹ÝÀÀ
  • recruiting response
    µ¿¿ø¹ÝÀÀ
  • response
    ¹ÝÀÀ
  • response bias
    ¹ÝÀÀÄ¡¿ìħ
  • response curve
    ¹ÝÀÀ°î¼±
  • response decline
    ¹ÝÀÀ°¨¼Ò
  • response frequency
    ¹ÝÀÀÁ֯ļö
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • heat shock response
    ¿­Ãæ°Ý¹ÝÀÀ
  • idiosyncratic drug response
    ƯÀ̾๰¹ÝÀÀ
  • immune response
    ¸é¿ª¹ÝÀÀ
  • immune response suppression
    ¸é¿ª¹ÝÀÀ¾ïÁ¦
  • inert response
    ºÒȰ¼º¹ÝÀÀ
  • inflammatory response
    ¿°Áõ¹ÝÀÀ
  • inspiratory triggering response time
    µé¼ûÀ¯¹ß¹ÝÀÀ½Ã°£
  • inverse response
    ¿ª¹ÝÀÀ
  • lytic response
    ¿ëÇØ¹ÝÀÀ
  • memory immune response
    ¸é¿ª±â¾ï¹ÝÀÀ
  • microphonic response
    ¸¶ÀÌÅ©·ÎÆù¹ÝÀÀ
  • myotactic response
    ±ÙÀ°½ÅÀü¹ÝÀÀ
  • response modulation
    ¹ÝÀÀÁ¶Á¤
  • placebo response
    ¼ÓÀÓ¾à¹ÝÀÀ
  • primary immune response
    ÀÏÂ÷¸é¿ª¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • adcc(antibody dependent cell mediated cytotoxicity)
    Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º(ù÷ô÷ëîðíá¬øàØÚË¿á¬øàÔ¸àõ)
  • albumin agglutinating antibody
    ¾ËºÎ¹ÎÀÀÁýÇ×ü(¡­ëêó¢ù÷ô÷).
  • anti-La antibody
    Ç×LaÇ×ü
  • anti-RNP antibody
    Ç× RNPÇ×ü
  • anti-Ro antibody
    Ç× RoÇ×ü
  • anti-SM antibody
    Ç×SMÇ×ü
  • anti-cardiolipin antibody
    Ç×Ä«µð¿À¸®ÇÉÇ×ü
  • anti-idiotype antibody
    Ç×À̵ð¿ÀŸÀÔÇ×ü, Ç×°³º°Æ¯ÀÌÇüÇ×ü
  • anti-sm antibody
    Ç×Sm Ç×ü(ù÷¡­ù÷ô÷)
  • antibody
    Ç×ü(ù÷ô÷)
  • antibody
    Ç×ü(ù÷ô÷)
  • antibody
    Ç×ü
  • antibody absorption
    Ç×üÈíÂø
  • antibody absorption test
    Ç×üÈí¼ö½ÃÇè(ù÷ô÷ýåâ¥ãËúÐ).
  • antibody binding site
    Ç×ü°áÇÕºÎÀ§
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • immune response gene
    ¸é¿ª¹ÝÀÀÀ¯ÀüÀÚ
  • immune response gene
    ¸é¿ª¹ÝÀÀÀ¯ÀüÀÚ.
  • immune response suppression
    ¸é¿ª¹ÝÀÀ¾ïÁ¦<--¾ï¾Ð>
  • immune response, primary
    ÀÏÂ÷¸é¿ª¹ÝÀÀ
  • immunologic response
    ¸é¿ª¹ÝÀÀ.
  • immunological response
    ¸é¿ªÇÐÀû¹ÝÀÀ
  • inert response
    ºÒȰ¼º ¹ÝÀÀ
  • inspiratory triggering response time
    Èí±âÀ¯¹ß¹ÝÀÀ½Ã°£.
  • inverse response
    ¿ª¹ÝÀÀ(æ½Úãëë).
  • local response
    ±¹¼Ò¹ÝÀÀ(¡­Úãëë).
  • lytic response
    ¿ë±Õ¹ÝÀÀ
  • memory immune response
    ¸é¿ªÇÐÀû±â¾ï¹ÝÀÀ
  • microphonic response
    ¸¶ÀÌÅ©·ÎÆù¹ÝÀÀ (¡­Úãëë).
  • microphonic response
    ¸¶ÀÌÅ©·ÎÆù¹ÝÀÀ
  • mixed lymphocyte response(MLR)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • antibody heterogeneity
    Ç×ü ºÒ±ÕÀϼº(ù÷ô÷ÝÕгìéàõ)
  • antibody mediated hypersensitivity
    Ç×ü ¸Å°³ °ú¹ÎÁõ(ù÷ô÷ØÚ˿ΦÚÂñø)
  • antibody specificity
    Ç×ü ƯÀ̼º(ù÷ô÷÷åì¶àõ)
  • antibody titer
    Ç×ü¿ª°¡(ù÷ô÷æ³Ê¤)
  • antibody valence
    Ç×ü°¡(ù÷ô÷ʤ)
  • antibody-excess zone
    Ç×ü°úÀ×±¸¿ª(ù÷ô÷Φí¥Ï¡æ´)
  • anticomplement fluorescent antibody technique
    Ç׺¸Ã¼ Çü±¤Ç×ü¼ú(ù÷ÜÍô÷û«ÎÃù÷ô÷âú)
  • antigen-antibody complex
    Ç׿øÇ×ü º¹ÇÕü(ù÷ê«ù÷ô÷ ÜÜùêô÷)
  • antigen-antibody lattice
    Ç׿øÇ×ü °ÝÀÚ(ù÷ê«ù÷ô÷ Ì«í­)
  • antigen-antibody reaction
    Ç׿øÇ×ü ¹ÝÀÀ(ù÷ê«ù÷ô÷Úãëë)
  • bifunctional antibody
    ¾ç±â´É Ç×ü(å»Ñ¦Òö ù÷ô÷)
  • bispecific antibody
    ¾çƯÀ̼º Ç×ü(å»÷åì¶àõù÷ô÷)
  • blocking antibody
    Â÷´ÜÇ×ü(ó´Ó¨ù÷ô÷)
  • catalytic antibody
    Ã˸ÅÇ×ü(õºØÚù÷ô÷)
  • cold antibody
    ³ÃÇ×ü(Ò²ù÷ô÷)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
AIA allylisopropylacetamide; amylase inhibitor activity; anti-immunoglobulin antibody; anti-insulin anti...
ANA acetylneuraminic acid; American Narcolepsy Association; American Neurological Association; American ...
APA action potential amplitude; aldosterone-producing adenoma; Ambulatory Pediatric Association; America...
ATA alimentary toxic aleukia; American Thyroid Association; aminotriazole; antithymic activity; antithyr...
EA early antigen; educational age; egg albumin; electric affinity; electrical activity; electroacupunct...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
ANCA Anti-neutrophil cytoplasm antibody
ANA Anti-nuclear antibody
APS Anti-phospholipid Antibody Syndrome
aPL Anti-phospholipid antibody
Ab Antibody
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • secondary osteon
    ÀÌÂ÷ »À ´ÜÀ§
  • secondary pain
    ¼Ó¹ß¼º ÅëÁõ, Á¦ÀÌ µ¿Åë
    µ¿ÀǾî=referred
  • secondary palate
    ÀÌÂ÷ ±¸°³
  • secondary pathway
    ÀÌÂ÷ °æ·Î
  • secondary pneumonia
    ¼Ó¹ß¼º Æó·Å
  • secondary sex characteristic
    ÀÌÂ÷ ¼ºÂ¡
  • secondary source
    ÀÌÂ÷ ¿äÀÎ
  • secondary sterility
    ¼Ó¹ß ºÒÀÓ
  • secondary structure
    ÀÌÂ÷ ±¸Á¶
  • secondary syphilis
    ÀÌÂ÷ ¸Åµ¶, 2±â ¸Åµ¶
    s
  • secondary thrombocytopenia
    ÀÌÂ÷¼º Ç÷¼ÒÆÇ °¨¼ÒÁõ
  • secondary tuberculosis
    ÀÌÂ÷¼º °áÇÙ
  • secondary vaccinia
    ÀÌÂ÷ ¹é½Å
  • agglutination antibody titer
    ÀÀÁý Ç×ü ¿ª°¡
  • albumin agglutinating antibody
    ¾ËºÎ¹Î ÀÀÁý Ç×ü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
flight or fight response See: emergency theory.
(05 Mar 2000)
late-phase response Recurrence of symptoms after an appreciable interval following challenge with an antigen; preceded by an initial early-phase response.
(05 Mar 2000)
lh response to gnrh This test measures the level of luteinising hormone in the blood after an injection of gonadotrophin releasing hormone (GNRH), normally produced in the hypothalamus. This will test the ability of the pituitary gland to respond by measuring one of the pituitary glands byproducts, luteinising hormone. This test is used to differentiate hypogonadism (ovary or testes) into primary hypogonadism (problem is with the ovary or testes) or secondary hypogonadism (problem is with the pituitary gland or the hypothalamus).
(27 Sep 1997)
lymphoproliferative response <haematology, immunology> A specific immune response that entails rapid T-cell replication. Standard antigens, such as tetanus toxoid, that elicit this response are used in lab tests of immune competence.
(13 Nov 1997)
affinity antibody The measure of the interaction between molecules such as a receptor and its ligand. This interaction is reversible.
(05 Mar 2000)
agglutinating antibody 1. An antibody that causes clumping or agglutination of the bacteria or other cells which either stimulated the formation of the agglutinin, or contain immunologically similar, reactive antigen.
Synonym: agglutinating antibody, immune agglutinin.
2. A substance, other than a specific agglutinating antibody, that causes organic particles to agglutinate, commonly qualified, e.g., plant agglutinin.
(05 Mar 2000)
anaphylactic antibody Antibody that has an affinity for certain kinds of cells, in addition to and unrelated to its specific affinity for the antigen that induced it, because of the properties of the Fc portion of the heavy chain.
See: heterocytotropic antibody, homocytotropic antibody, cytotropic antibody test.
Synonym: anaphylactic antibody, cytophilic antibody.
(05 Mar 2000)
anti-basement membrane antibody Autoantibodies to renal glomerular basement membrane antigens.
(05 Mar 2000)
antibody An immunoglobulin molecule that has a specific amino acid sequence by virtue of which it interacts only with the antigen that induced its synthesis in cells of the lymphoid series (especially plasma cells) or with antigen closely related to it. Antibodies are classified according to their ode of action as agglutinins, bacteriolysins, haemolysins, opsonins, precipitins, etc.
(18 Nov 1997)
antibody affinity A measure of the binding strength between antibody and a simple hapten or antigen determinant. It depends on the closeness of stereochemical fit between antibody combining sites and antigen determinants, on the size of the area of contact between them, and on the distribution of charged and hydrophobic groups. It includes the concept of "avidity," which refers to the strength of the antigen-antibody bond after formation of reversible complexes.
(12 Dec 1998)
antibody aldolase <enzyme> Prepared by reactive immuninization to catalyze a wide variety of aldol reactions and decarboxylations
Registry number: EC 4.1.2.-
Synonym: fab 33f12, aldolase catalytic antibody
(26 Jun 1999)
antibody-coated bacteria test, urinary Fluorescent antibody technique for visualizing antibody-bacteria complexes in urine. The presence or absence of antibody-coated bacteria in urine correlates with localization of urinary tract infection in the kidney or bladder, respectively.
(12 Dec 1998)
antibody combining site <immunology> In immune network theory, an idiotope, an antigenic site of an antibody that is responsible for that antibody binding to an antigenic determinant (epitope).
Also used of the site on a ligand molecule to which a cell surface receptor binds.
(18 Nov 1997)
antibody deficiency disease <syndrome> Any of a group of disorders associated with a defective antibody production due to defects in the B-type lymphocyte system or in T-type lymphocytes; chief manifestation is an increased susceptibility to infection by various microorganisms.
See: agammaglobulinaemia, hypogammaglobulinaemia, immunodeficiency.
Synonym: antibody deficiency disease.
(05 Mar 2000)
antibody deficiency syndrome <syndrome> Any of a group of disorders associated with a defective antibody production due to defects in the B-type lymphocyte system or in T-type lymphocytes; chief manifestation is an increased susceptibility to infection by various microorganisms.
See: agammaglobulinaemia, hypogammaglobulinaemia, immunodeficiency.
Synonym: antibody deficiency disease.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á